Advertisement

Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability

  • Antonis Tsiailanis
  • Maria Tsoumani
  • Evgenios K. Stylos
  • Maria V. Chatziathanasiadou
  • Tahsin F. Kellici
  • Thomas Mavromoustakos
  • Alexandros D. Tselepis
  • Andreas G. Tzakos
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1824)

Abstract

Cardiovascular diseases (CVDs) are becoming major contributors to the burden of disease due to genetic and environmental factors. Despite current standard oral care, cardiovascular risk remains relatively high. A triple antiplatelet therapy with a cyclooxygenase-1 (COX-1) inhibitor, a P2Y12 receptor antagonist, and a protease-activated receptor-1 (PAR-1) antagonist has been established in the secondary prevention of atherothrombosis in patients with acute myocardial infraction and in those with peripheral artery disease. However, due to the combinatorial use of three different drugs, patients receiving this triple therapy are exposed to enhanced risk of bleeding. Conforming to polypharmacology principles, the discovery of a single compound that can simultaneously block the three platelet activation pathways (PAR-1, P2Y12, and COX-1) is of importance. Natural products have served as an inexhaustible source of bioactive compounds presenting a diverse pharmaceutical profile, including anti-inflammatory, antioxidant, anticancer, and antithrombotic activity. Indeed, principal component analysis indicated that natural products have the potential to inhibit the three aforementioned pathways, though existed reports refer to single inhibition mechanism on specific receptor(s) implicated in platelet activation. We thus set out to explore possibilities that take advantage of this potential of natural products and shape the basis to produce novel compounds that could simultaneously target PAR-1, P2Y12, and COX-1 platelet activation pathways. Polyunsaturated fatty acids (PUFAs) have multiple effects leading to improvements in blood pressure and cardiac function and arterial compliance. A promising approach to achieve the desirable goal is the bioconjugation of natural products with PUFAs. Herein, we describe the principles that should be followed to develop molecular hybrids bearing triple antiplatelet activity profile.

Key words

Triple antiplatelet activity Flavonoids Liquid chromatography Plasma stability LC-MS Polyunsaturated fatty acids 

References

  1. 1.
    Tsoumani ME, Tselepis AD (2017) Antiplatelet agents and anticoagulants: from pharmacology to clinical practice. Curr Pharm Des 23(9):1279–1293. https://doi.org/10.2174/1381612823666170124141806 CrossRefPubMedGoogle Scholar
  2. 2.
    Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999–3054. https://doi.org/10.1093/eurheartj/ehr236 CrossRefGoogle Scholar
  3. 3.
    Diehl P, Bode C, Duerschmied D (2015) Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Ther Clin Risk Manag 11:1133–1138. https://doi.org/10.2147/TCRM.S55469 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Costa F, Windecker S, Valgimigli M (2017) Dual antiplatelet therapy duration: reconciling the inconsistencies. Drugs 77(16):1733–1754. https://doi.org/10.1007/s40265-017-0806-1 CrossRefPubMedGoogle Scholar
  5. 5.
    Agarwal N, Jain A, Mahmoud AN et al (2017) Safety and efficacy of dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention. Am J Med 130(11):1280–1289. https://doi.org/10.1016/j.amjmed.2017.03.057 CrossRefPubMedGoogle Scholar
  6. 6.
    Moschonas IC, Goudevenos JA, Tselepis AD (2015) Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. Int J Cardiol 185:9–18. https://doi.org/10.1016/j.ijcard.2015.03.049 CrossRefPubMedGoogle Scholar
  7. 7.
    Kontogianni VG, Tsoumani ME, Kellici TF et al (2016) Deconvoluting the dual antiplatelet activity of a plant extract. J Agric Food Chem 64(22):4511–4521. https://doi.org/10.1021/acs.jafc.6b00544 CrossRefPubMedGoogle Scholar
  8. 8.
    Hertog MG, Feskens EJ, Hollman PC et al (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342(8878):1007–1011CrossRefPubMedGoogle Scholar
  9. 9.
    Palomo I, Toro C, Alarcon M (2008) The role of platelets in the pathophysiology of atherosclerosis (review). Mol Med Rep 1(2):179–184PubMedGoogle Scholar
  10. 10.
    Manach C, Williamson G, Morand C et al (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81(1 Suppl):230S–242SCrossRefPubMedGoogle Scholar
  11. 11.
    Stylos E, Chatziathanasiadou MV, Tsiailanis A et al (2017) Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. Biochim Biophys Acta 1861(11 Pt A):2609–2618. https://doi.org/10.1016/j.bbagen.2017.08.018 CrossRefGoogle Scholar
  12. 12.
    Schrödinger Release 2015–2 (2015) Maestro, version 10.5, Schrödinger, LLC, New York, NYGoogle Scholar
  13. 13.
    Schrödinger Release 2015–2 (2015) LigPrep, version 3.4, Schrödinger, LLC, New York, NYGoogle Scholar
  14. 14.
    Harder E, Damm W, Maple J et al (2016) OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 12(1):281–296. https://doi.org/10.1021/acs.jctc.5b00864 CrossRefPubMedGoogle Scholar
  15. 15.
    Small-Molecule Drug Discovery Suite 2015–2 (2015) QikProp, version 4.4, Schrödinger, LLC, New York, NYGoogle Scholar
  16. 16.
    Schrödinger Release 2015–2 (2015) Canvas, version 2.4, Schrödinger, LLC, New York, NYGoogle Scholar
  17. 17.
    Di L, Kerns EH, Hong Y et al (2005) Development and application of high throughput plasma stability assay for drug discovery. Int J Pharm 297(1–2):110–119. https://doi.org/10.1016/j.ijpharm.2005.03.022 CrossRefPubMedGoogle Scholar
  18. 18.
    Kerns EH, Di L (2008) Chapter 12 - plasma stability. In: Drug-like properties: concepts, structure design and methods. Academic Press, San Diego, CA, pp 169–177. https://doi.org/10.1016/B978-012369520-8.50013-9 CrossRefGoogle Scholar
  19. 19.
    Cattaneo M, Cerletti C, Harrison P et al (2013) Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost. https://doi.org/10.1111/jth.12231 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Antonis Tsiailanis
    • 1
  • Maria Tsoumani
    • 2
  • Evgenios K. Stylos
    • 1
    • 3
  • Maria V. Chatziathanasiadou
    • 1
  • Tahsin F. Kellici
    • 4
  • Thomas Mavromoustakos
    • 4
  • Alexandros D. Tselepis
    • 2
  • Andreas G. Tzakos
    • 1
  1. 1.Section of Organic Chemistry and Biochemistry, Department of ChemistryUniversity of IoanninaIoanninaGreece
  2. 2.Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of ChemistryUniversity of IoanninaIoanninaGreece
  3. 3.Biotechnology Laboratory, Department of Biological Applications and TechnologyUniversity of IoanninaIoanninaGreece
  4. 4.Division of Organic Chemistry, Department of ChemistryNational and Kapodistrian University of Athens, Panepistimiopolis ZografouAthensGreece

Personalised recommendations